Charles McDermott

Charles McDermott is President, Chief Executive Officer & Director at Primmune Therapeutics, Inc. since 2019.
Mr. McDermott is Chairman at Anavo Therapeutics BV.
Mr. McDermott is Independent Director at Equillium, Inc. since 2018.
Mr. McDermott is Managing Member at McDermott Consulting since 2018.
Formerly, Mr. McDermott was Director, VP-Business Development & Eye Care at Allergan, Inc. from 2005 to 2013.
Mr. McDermott was President, Director & Chief Business Officer at Impact Biomedicines, Inc. from 2017 to 2018.
Mr. McDermott was Research Scientist at Agouron Pharmaceuticals LLC.
Mr. McDermott was Principal at deCODE genetics, Inc. from 2001 to 2005.
Mr. McDermott was President & Chief Business Officer at Kala Bio, Inc. from 2014 to 2017.
Education includes graduate studies at the University of California, Santa Barbara, undergraduate studies at the University of California, Santa Cruz, and an MBA from the University of San Diego.